Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 0.74%.

  • BridgeBio Pharma's Return on Capital Employed rose 1800.0% to 0.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74%, marking a year-over-year increase of 1800.0%. This contributed to the annual value of 1.03% for FY2024, which is 3500.0% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Return on Capital Employed is 0.74%, which was up 1800.0% from 0.82% recorded in Q2 2025.
  • BridgeBio Pharma's Return on Capital Employed's 5-year high stood at 0.53% during Q2 2021, with a 5-year trough of 1.33% in Q4 2023.
  • Over the past 5 years, BridgeBio Pharma's median Return on Capital Employed value was 0.82% (recorded in 2022), while the average stood at 0.86%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first crashed by -4100bps in 2023, then surged by 4300bps in 2024.
  • BridgeBio Pharma's Return on Capital Employed (Quarter) stood at 0.76% in 2021, then fell by -22bps to 0.92% in 2022, then plummeted by -44bps to 1.33% in 2023, then surged by 30bps to 0.93% in 2024, then grew by 20bps to 0.74% in 2025.
  • Its last three reported values are 0.74% in Q3 2025, 0.82% for Q2 2025, and 0.93% during Q1 2025.